Date: 2015-10-21
Type of information: Nomination
Compound:
Company: DBV Technologies (France)
Therapeutic area: Allergic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On October 21, 2015, DBV Technologies announced that Michael J. Goller has been appointed to its Board of Directors effective October 21, 2015. Mr. Goller is a Managing Director of Baker Brothers Investments, DBV’s largest shareholder. Mr. Goller has been appointed to the Board of Directors to replace Dr. Rafaèle Tordjman from Sofinnova Partners, which reflects changes in the company’s principal shareholders. Dr. Tordjman will retire from the Board after 10 years of service. Michael Goller serves as a Managing Director of Baker Brothers Investments, a fund management company focused on long-term investments in life-sciences companies. Prior to joining Baker Brothers in 2005, Mr. Goller was an Associate of JPMorgan Partners, LLC where he focused on venture investments in the life sciences sector from 1999 to 2003. Mr. Goller began his career as an investment banker with Merrill Lynch and Co. from 1997 to 1999. Mr. Goller holds a B.S. in Molecular and Cell Biology from The Pennsylvania State University, and a Master\'s in both Biotechnology (School of Engineered and Applied Sciences) and Business Administration (Wharton School) from the University of Pennsylvania.
Financial terms:
Latest news:
